Company Encyclopedia
View More
name
MODERN CHI MED
01643.HK
Modern Chinese Medicine Group Co., Ltd., an investment holding company, engages in the production and sale of proprietary Chinese medicines for elderlies and middle aged in the People's Republic of China. It provides vigour and vitality supplement, circulation enhancement pills, cardiotonic enhancement capsules, heart wellness capsules, menstrual discomfort relief, liver detox tablets, liver-dispersing and stomach regulating pills, fever- removing and detoxification pills, kidney invigoration pills, and huoxiang zheng qi pills. The company offers its products as therapeutics for the treatment of qi-deficiency and blood-statis, cardio-cerebrovascular, digestive and gastrointestinal, gynecological, and for symptoms of COVID-19 and similar illnesses. It also provides business support, technical, and consulting services.
1.425 T
01643.HKMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking32/47
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.99%C
    • Profit Margin9.38%B
    • Gross Margin25.00%C
  • Growth ScoreD
    • Revenue YoY-15.83%E
    • Net Profit YoY32.31%B
    • Total Assets YoY8.74%B
    • Net Assets YoY5.99%B
  • Cash ScoreC
    • Cash Flow Margin1065.62%B
    • OCF YoY-15.83%E
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreA
    • Gearing Ratio8.85%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Performance" MODERN CHI MED's interim net profit is 2.45 million RMB, turning losses into profits

    MODERN CHI MED announced its interim results for the six months ending in June, with revenue of RMB 64.76 million, a year-on-year decrease of 15.5%. It recorded a net profit of RMB 2.45 million, compared to a loss of RMB 6.85 million in the same period last year, turning from loss to profit; earnings per share were 0.41 cents. No dividend was declared

    AASTOCKS·
    HK
    01643
    -4.23%
    AASTOCKS·
    HK
    01643
    -4.23%

    MODERN CHI MED released its interim results, with a profit attributable to shareholders of 2.5 million yuan, turning a profit compared to the same period last year

    According to the Zhitong Finance APP, MODERN CHI MED released its performance for the six months ending June 30, 2025. The group achieved revenue of RMB 64.8 million during the period, a year-on-year decrease of 15.4%; the profit attributable to the company's owners was RMB 2.5 million, turning a profit compared to the previous year; the basic earnings per share were 0.41 cents

    Zhitong·
    HK
    01643
    -4.23%
    Zhitong·
    HK
    01643
    -4.23%

    "Profit Alert" MODERN CHI MED forecasts a profit of at least 2 million RMB in the first half of the year

    Modern Chi Med Group issued a profit warning, expecting a profit of no less than 2 million RMB for the six months ending in June, compared to a loss of 6.9 million RMB in the same period last year. The turnaround from loss to profit is mainly due to a significant reduction in losses from the disposal of properties, plants, and equipment

    AASTOCKS·
    HK
    01643
    -4.23%
    AASTOCKS·
    HK
    01643
    -4.23%

    Modern Chi Med Group issues a profit warning, expecting interim profit attributable to shareholders to be no less than HKD 2 million, turning from loss to profit year-on-year

    MODERN CHI MED expects that the interim profit attributable to shareholders for the period ending June 30, 2025, will not be less than HKD 2 million, achieving a turnaround from a loss of HKD 6.9 million in the same period of 2024. The improvement in performance is mainly attributed to a significant reduction in losses from the disposal of properties, plants, and equipment, although revenue is expected to decrease by 15% to 20% due to intense industry competition

    Zhitong·
    HK
    01643
    -4.23%
    Zhitong·
    HK
    01643
    -4.23%

    The 8th Changbai Mountain Pharmaceutical and Health Industry Development Forum was held in Tonghua

    On August 10th, the 15th Northeast Asia Expo - the 8th Changbai Mountain Pharmaceutical Health Industry Development Forum was held in Tonghua City, Jilin Province. It is understood that Tonghua, as the "Chinese Medicine City" and "Hometown of Ginseng," has gradually formed a diversified industrial development pattern supported by modern traditional Chinese medicine, biopharmaceuticals, chemical drugs, and medical devices. This event announced the geographical indication certification trademark for "Tonghua Ginseng," and signed the commissioning agreement for the compilation of the "Tonghua Ginseng Annual Industry Development Report" and the cooperation agreement for the Health Product R&D and Production Service Center

    Zhitong·
    HK
    01643
    -4.23%
    SH
    600056
    +0.27%
    Zhitong·
    HK
    01643
    -4.23%
    SH
    600056
    +0.27%